SHP099
SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM) . SHP099 inhibits RAS-ERK signaling and inhibits tumor growth[1][2].
Product Specifications
CAS Number
[1801747-42-1]
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Phosphatase; SHP2
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SHP099.html
Purity
99.81
Solubility
DMSO : 12 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
NC1=NC(N2CCC(C)(N)CC2)=CN=C1C3=CC=CC(Cl)=C3Cl
Molecular Formula
C16H19Cl2N5
Molecular Weight
352.26
Precautions
H315, H319, H320
References & Citations
[2]Sun X, et al. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia. 2018 May;32 (5) :1246-1249.|[1]Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535 (7610) :148-52.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
ACS Nano. 2023 Aug 22;17 (16) :16056-16068.|Acta Pharm Sin B. 2022 Jan;12 (1) :149-166.|Acta Pharm Sin B. 2022 Jul;12 (7) :3073-3084.|Acta Pharm Sin B. 2024 Jun;14 (6) :2598-2612.|Ann Transl Med. 2020 Dec;8 (23) :1570.|Biochem Biophys Res Commun. 2023 Oct 8:676:121-131.|Biochem Biophys Res Commun. 2024 May 21:709:149812.|Biochem Biophys Res Commun. 2025 Jun 14:776:152209.|bioRxiv. 2019 Sep.|bioRxiv. 2024 Feb 5.|bioRxiv. 2024 November 06.|bioRxiv. 2025 Aug 2:2025.07.31.667978.|bioRxiv. 2025 Oct 26.|Br J Cancer. 2023 Feb;128 (4) :678-690.|Brain Pathol. 2020 Mar;30 (2) :373-385.|Cancer Cell Int. 2021 Jul 3;21 (1) :337.|Cancer Res Commun. 2022 Sep;2 (9) :1061-1074.|Cancer Res. 2021 Jun 15;81 (12) :3215-3228.|Cancers (Basel) . 2022 May 12;14 (10) :2377.|Cell Rep. 2019 Aug 27;28 (9) :2331-2344.e8.|Cell Rep. 2019 Aug 27;28 (9) :2331-2344.e8.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Commun Biol. 2020 Mar 17;3 (1) :128. |Eur J Med Chem. 2025 Jun 27:297:117918.|Exp Cell Res. 2022 Nov 15;420 (2) :113361.|Exp Mol Med. 2020 Jun;52 (6) :911-920.|Exp Ther Med. 2022 Apr;23 (4) :302.|FEBS Open Bio. 2020 Dec;10 (12) :2578-2587.|Front Immunol. 2021 Jan 21:11:610523.|Hematol Oncol. 2024 Jan;42 (1) :e3233.|Hepatology. 2018 Jul;68 (1) :333-348.|Hepatology. 2020 Jul;72 (1) :155-168. |Inflamm Res. 2023 Jul;72 (7) :1501-1512.|J Biol Chem. 2024 Jul 30:107616.|J Cell Biol. 2025 Oct 16;224 (12) .|J Exp Med. 2022 Apr 4;219 (4) :e20210739.|J Histochem Cytochem. 2025 Jan-Feb;73 (1-2) :63-79.|J Immunol Res. 2020 Jun 19;2020:4598476.|J Immunol. 2021 Sep 1;207 (5) :1419-1427.|J Magn Reson Imaging. 2025 Apr;61 (4) :1996-2008.|J Orthop Translat. 2022 Feb 17;32:112-120.|MedComm (2020) . 2022 Mar 4;3 (1) :e120.|Microvasc Res. 2022 Sep:143:104397.|Mol Cell. 2021 Oct 7;81 (19) :4076-4090.e8.|Mol Med. 2024 Apr 9;30 (1) :47.|Nano Today. 2025 Apr.|Nat Chem Biol. 2025 Aug;21 (8) :1226-1237.|Nat Commun. 2019 Apr 1;10 (1) :1473. |Nat Commun. 2023 Apr 6;14 (1) :1933.|Nat Commun. 2018 Oct 30;9 (1) :4507. |Nat Immunol. 2021 Nov;22 (11) :1391-1402.|Neural Regen Res. 2025 Mar 1;20 (3) :858-872.|Neuro Oncol. 2019 Nov 4;21 (11) :1423-1435. |Neuro Oncol. 2025 Mar 6:noaf057.|NPJ Precis Oncol. 2024 Jul 16;8 (1) :144.|Patent. US20190231805A1.|Patent. US20220380385A1.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Mar.|Sci Rep. 2023 Jun 20;13 (1) :10041.|Sci Transl Med. 2025 May 7;17 (797) :eads2694.|Signal Transduct Target Ther. 2022 Sep 12;7 (1) :317.|SSRN. 2020 May.|Theranostics. 2021 Jan 1;11 (2) :555-566.|Thromb Res. 2023 Aug:228:105-116.|Acta Pharm Sin B. 2022 Jan;12 (1) :149-166.|Cancer Discov. 2018 Oct;8 (10) :1237-1249. |Cancer Res Commun. 2023 Dec 27;3 (12) :2608-2622.|Cancer Res. 2020 Aug 15;80 (16) :3413-3423.|Inflammation. 2021 Aug;44 (4) :1529-1539.|J Control Release. 2025 May 25:384:113889.|Open Biol. 2017 May;7 (5) . pii: 170066.|Patent. US20200330595A1.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6242906-01 0.1 mL
Aggrecan (Proteoglycan, PG, AGC 1, Aggrecan 1, Antigen identified by monoclonal A0122, Cartilage specific proteoglycan core protein, Chondroitin sulfate proteoglycan core protein 1, CSPCP, CSPG1, CSPGCP, Large aggregating proteoglycan, MSK16, SEDK) (Bioti
Ask
View Details MBS6242906-02 5x 0.1 mL
Aggrecan (Proteoglycan, PG, AGC 1, Aggrecan 1, Antigen identified by monoclonal A0122, Cartilage specific proteoglycan core protein, Chondroitin sulfate proteoglycan core protein 1, CSPCP, CSPG1, CSPGCP, Large aggregating proteoglycan, MSK16, SEDK) (Bioti
Ask
View Details 
38948156 3x 1.0 µg DNA
RGD1305713 CRISPR All-in-one AAV vector set (with saCas9)(Rat)
Ask
View Details 126033-ML490 100 µL
DST (Dystonin, 230kD Bullous Pemphigoid Antigen, 230/240kD Bullous Pemphigoid Antigen, Bullous Pemphigoid Antigen 1, BPA, Bullous Pemphigoid Antigen, Dystonia Musculorum Protein, Hemidesmosomal Plaque Protein, BP230, BP240, BPAG1, DMH, DT, KIAA0728) (MaxLight 490)
Ask
View Details